Anixa Biosciences To Host Conference Call This Evening To Discuss New Data From Ongoing Phase 1 Study Of Breast Cancer Vaccine
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences, Inc. (NASDAQ:ANIX) is set to release new data from its ongoing Phase 1 breast cancer vaccine trial after a presentation at the 2023 SABCS. A conference call is scheduled for today at 6:30 p.m. ET to discuss the findings. The vaccine was first administered in 2021 to a Triple Negative Breast Cancer survivor. Key Opinion Leaders in oncology, including the inventor of Herceptin, Dr. H. Michael Shepard, and Dr. Brian Leyland-Jones, are advisors to Anixa and will participate in the call.
December 06, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences is releasing new data from its Phase 1 breast cancer vaccine trial, which could significantly impact the company's stock price depending on the results.
The release of new clinical trial data is a pivotal event for biotech companies like Anixa Biosciences. Positive results from the Phase 1 trial could lead to increased investor confidence and a potential rise in stock price due to the progress in developing a novel breast cancer vaccine. The involvement of renowned oncology experts and the historical significance of Herceptin, a drug with substantial sales and impact, further underscore the importance of this event for Anixa.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100